LD-2 disclosure · 4th Quarter - Report
AMRYT PHARMA
Client
- Name
- AMRYT PHARMA
- Description
- Rare disease biopharmaceutical company
- Location
- Massachusetts · United States of America
Registrant
- Description
- Health care consulting
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesHealth Issues
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes; HR 5539 Orphan Cures Act
LobbyistsAMY JENSEN · SARAH KUEHL EGGE · mrs KRISTEN ELIZABETH SHATYNSKI
Covered position (AMY JENSEN): 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Legislative Affairs
Covered position (SARAH KUEHL EGGE): Legislative Assistant to Senator Bob Kerrey; Senior Budget Analyst for Democratic staff of the Senate Budget Committee (Sen. Kent Conrad); Deputy Staff Director, Joint Select Committee on Deficit Reduction
Covered position (mrs KRISTEN ELIZABETH SHATYNSKI): Professional Staff, House E&C Committee to Cathy McMorris Rodgers (2021-22) & Greg Walden (2017-21); Leg. Asst., Rep. Greg Walden, 4/2015-1/2017; Leg. Asst., Rep. Jackie Walorski, 10/2013-4/2015; Leg. Asst., Rep. Devin Nunes, 10/2012-10/2013
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
LobbyistsAMY JENSEN · SARAH KUEHL EGGE · mrs KRISTEN ELIZABETH SHATYNSKI
1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Legislative Affairs